StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3010% below fair value
$156.59−6.27 (-3.85%)

Close on Nov 19, 2026Market cap $15.92BP/E 23.0Yield –

Neurocrine Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Neurocrine Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was $870.40M, up 64.6% year over year. For fiscal 2025 it was $748.70M, up 34.4% from the year before. The highest annual figure on record is $748.70M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$748.70M+34.4%
FY2024Dec 31, 2024$557.20M+54.1%
FY2023Dec 31, 2023$361.60M+12.0%
FY2022Dec 31, 2022$322.90M+38.5%
FY2021Dec 31, 2021$233.10M+7.1%
FY2020Dec 31, 2020$217.60M+64.5%
FY2019Dec 31, 2019$132.30M+72.7%
FY2018Dec 31, 2018$76.60M–
FY2017Dec 31, 2017-$101.27M–
FY2016Dec 31, 2016-$110.29M–
FY2015Dec 31, 2015-$39.93M–
FY2014Dec 31, 2014-$48.75M–
FY2013Dec 31, 2013-$30.15M–
FY2012Dec 31, 2012-$36.27M–
FY2011Dec 31, 2011-$1.45M-102.9%
FY2010Dec 31, 2010$49.63M–
FY2009Dec 31, 2009-$53.13M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$128.60M+43.7%
Q1 FY2026Mar 31, 2026$136.70M+152.7%
Q4 FY2025Dec 31, 2025$390.80M+66.2%
Q3 FY2025Sep 30, 2025$214.30M+43.0%
Q2 FY2025Jun 30, 2025$89.50M+68.9%
Q1 FY2025Mar 31, 2025$54.10M-54.6%
Q4 FY2024Dec 31, 2024$235.20M+99.2%
Q3 FY2024Sep 30, 2024$149.90M-26.7%
Q2 FY2024Jun 30, 2024$53.00M-69.3%
Q1 FY2024Mar 31, 2024$119.10M–
Q4 FY2023Dec 31, 2023$118.10M-16.4%
Q3 FY2023Sep 30, 2023$204.40M+103.4%
Q2 FY2023Jun 30, 2023$172.80M+33.6%
Q1 FY2023Mar 31, 2023-$133.70M–
Q4 FY2022Dec 31, 2022$141.20M–
Q3 FY2022Sep 30, 2022$100.50M+79.1%
Q2 FY2022Jun 30, 2022$129.30M+30.7%
Q1 FY2022Mar 31, 2022-$48.10M-158.1%
Q4 FY2021Dec 31, 2021-$4.70M-105.2%
Q3 FY2021Sep 30, 2021$56.10M–
Q2 FY2021Jun 30, 2021$98.90M-13.4%
Q1 FY2021Mar 31, 2021$82.80M+142.1%
Q4 FY2020Dec 31, 2020$90.00M-5.0%
Q3 FY2020Sep 30, 2020-$20.80M-122.1%
Q2 FY2020Jun 30, 2020$114.20M+91.3%
Q1 FY2020Mar 31, 2020$34.20M–
Q4 FY2019Dec 31, 2019$94.70M+112.8%
Q3 FY2019Sep 30, 2019$94.30M+66.7%
Q2 FY2019Jun 30, 2019$59.70M+277.0%
Q1 FY2019Mar 31, 2019-$116.40M–
Q4 FY2018Dec 31, 2018$44.49M+16.5%
Q3 FY2018Sep 30, 2018$56.56M–
Q2 FY2018Jun 30, 2018$15.84M–
Q1 FY2018Mar 31, 2018-$40.29M–
Q4 FY2017Dec 31, 2017$38.20M–
Q3 FY2017Sep 30, 2017-$12.11M–
Q2 FY2017Jun 30, 2017-$48.64M–
Q1 FY2017Mar 31, 2017-$78.72M–
Q4 FY2016Dec 31, 2016-$31.97M–
Q3 FY2016Sep 30, 2016-$31.79M–

More Neurocrine Biosciences figures

See a number that looks wrong?